NYSEAMERICAN:PTN Palatin Technologies - PTN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Palatin Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.01 -0.09 (-2.90%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.84▼$3.0450-Day Range N/A52-Week Range$2.14▼$13.00Volume36,202 shsAverage Volume89,095 shsMarket Capitalization$28.08 millionP/E RatioN/ADividend YieldN/APrice Target$50.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Palatin Technologies MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,893.4% Upside$60.00 Price TargetShort InterestHealthy3.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.62) to ($3.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.72 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPalatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.00, Palatin Technologies has a forecasted upside of 1,893.4% from its current price of $3.01.Amount of Analyst CoveragePalatin Technologies has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.27% of the float of Palatin Technologies has been sold short.Short Interest Ratio / Days to CoverPalatin Technologies has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Palatin Technologies has recently decreased by 6.40%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPalatin Technologies does not currently pay a dividend.Dividend GrowthPalatin Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTN. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 4 people have searched for PTN on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Palatin Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Palatin Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.90% of the stock of Palatin Technologies is held by insiders.Percentage Held by InstitutionsOnly 9.03% of the stock of Palatin Technologies is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Palatin Technologies are expected to decrease in the coming year, from ($2.62) to ($3.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palatin Technologies is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palatin Technologies is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalatin Technologies has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Palatin Technologies (NYSEAMERICAN:PTN) StockPalatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.Read More Receive PTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address PTN Stock News HeadlinesMarch 16, 2023 | americanbankingnews.comPalatin Technologies' (PTN) "Buy" Rating Reiterated at HC WainwrightMarch 13, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Palatin Technologies (PTN), Stryker (SYK)March 26, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 2, 2023 | finance.yahoo.comFrontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel DiseaseFebruary 28, 2023 | markets.businessinsider.comPalatin Technologies Says USPTO Issues Patent On Vyleesi For Hypoactive Sexual Desire DisorderFebruary 28, 2023 | finance.yahoo.comPalatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled HypertensionFebruary 16, 2023 | benzinga.comPalatin Technologies Earnings Perspective: Return On Capital EmployedFebruary 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN) and Lantheus (LNTH)March 26, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!February 15, 2023 | finance.yahoo.comPalatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate UpdateFebruary 14, 2023 | msn.comEarnings Outlook For Palatin TechnologiesFebruary 10, 2023 | finance.yahoo.comPalatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023January 26, 2023 | finance.yahoo.comMyovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue EstimatesJanuary 19, 2023 | msn.comPalatin starts mid-stage study of bremelanotide for diabetic kidney diseaseJanuary 19, 2023 | finance.yahoo.comPalatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney DiseaseJanuary 18, 2023 | marketwatch.comPalatin Technologies Shares Jump on $4.7 Million Funding NewsJanuary 18, 2023 | finance.yahoo.comPalatin Receives $4.7 Million of Non-Dilutive FundingJanuary 10, 2023 | finance.yahoo.comFrontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory ConditionsJanuary 5, 2023 | finance.yahoo.comPalatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales ResultsJanuary 5, 2023 | thestreet.comPalatin Technologies (PTN) Stock Spikes Following FDA Approval of 'Female Viagra' TreatmentDecember 23, 2022 | benzinga.comPalatin Technologies's Return On Capital Employed InsightsNovember 14, 2022 | finance.yahoo.comPalatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue EstimatesNovember 10, 2022 | finance.yahoo.comSolid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue EstimatesNovember 9, 2022 | finance.yahoo.comArmata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue EstimatesOctober 31, 2022 | finance.yahoo.comPalatin Announces $10 Million Registered Direct OfferingOctober 24, 2022 | finance.yahoo.comPalatin Presents PL8177 Data at American College of Gastroenterology Annual MeetingOctober 20, 2022 | finance.yahoo.comFirst Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis TrialSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address PTN Company Calendar Last Earnings11/15/2021Today3/25/2023Next Earnings (Estimated)5/15/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:PTN Previous SymbolNYSE:PTN CUSIPN/A CIK911216 Webwww.palatin.com Phone(609) 495-2200Fax609-495-2202Employees26Year FoundedN/APrice Target and Rating Average Stock Price Forecast$60.00 High Stock Price Forecast$70.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+1,561.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,200,000.00 Net Margins-1,713.72% Pretax Margin-1,713.63% Return on Equity-169.74% Return on Assets-93.05% Debt Debt-to-Equity Ratio0.01 Current Ratio1.65 Quick Ratio1.60 Sales & Book Value Annual Sales$1.47 million Price / Sales19.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book1.71Miscellaneous Outstanding Shares9,330,000Free Float8,410,000Market Cap$28.08 million OptionableNot Optionable Beta0.96 Key ExecutivesCarl SpanaPresident, Chief Executive Officer & DirectorStephen T. WillsCOO, CFO, Secretary, Treasurer & Executive VPMichael B. RaizmanChief Medical OfficerJohn DoddSenior Vice President-Preclinical DevelopmentJames E. HattersleySenior Vice President-Business DevelopmentKey CompetitorsCumberland PharmaceuticalsNASDAQ:CPIXSatsuma PharmaceuticalsNASDAQ:STSANeoleukin TherapeuticsNASDAQ:NLTXKala PharmaceuticalsNASDAQ:KALACorbus PharmaceuticalsNASDAQ:CRBPView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 846,506 shares on 2/15/2023Ownership: 9.073%Millennium Management LLCBought 45,987 shares on 2/15/2023Ownership: 0.493%Morgan StanleySold 2,829 shares on 2/15/2023Ownership: 0.134%Geode Capital Management LLCSold 3,793 shares on 2/13/2023Ownership: 0.710%Dimensional Fund Advisors LPSold 5,378 shares on 2/9/2023Ownership: 0.188%View All Insider TransactionsView All Institutional Transactions PTN Stock - Frequently Asked Questions Should I buy or sell Palatin Technologies stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTN shares. View PTN analyst ratings or view top-rated stocks. What is Palatin Technologies' stock price forecast for 2023? 2 Wall Street analysts have issued 1 year target prices for Palatin Technologies' shares. Their PTN share price forecasts range from $50.00 to $70.00. On average, they expect the company's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 1,893.4% from the stock's current price. View analysts price targets for PTN or view top-rated stocks among Wall Street analysts. How have PTN shares performed in 2023? Palatin Technologies' stock was trading at $3.87 at the beginning of 2023. Since then, PTN shares have decreased by 22.2% and is now trading at $3.01. View the best growth stocks for 2023 here. When is Palatin Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023. View our PTN earnings forecast. How were Palatin Technologies' earnings last quarter? Palatin Technologies, Inc. (NYSEAMERICAN:PTN) announced its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.75). The biopharmaceutical company had revenue of $0.16 million for the quarter. Palatin Technologies had a negative trailing twelve-month return on equity of 169.74% and a negative net margin of 1,713.72%. During the same period in the prior year, the business earned ($0.50) earnings per share. When did Palatin Technologies' stock split? Palatin Technologies shares reverse split on the morning of Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Palatin Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM). What is Palatin Technologies' stock symbol? Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN." Who are Palatin Technologies' major shareholders? Palatin Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.07%), Geode Capital Management LLC (0.71%), Millennium Management LLC (0.49%), Dimensional Fund Advisors LP (0.19%), Morgan Stanley (0.13%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alan W Dunton and Robert K Deveer Jr. View institutional ownership trends. How do I buy shares of Palatin Technologies? Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Palatin Technologies' stock price today? One share of PTN stock can currently be purchased for approximately $3.01. How much money does Palatin Technologies make? Palatin Technologies (NYSEAMERICAN:PTN) has a market capitalization of $28.08 million and generates $1.47 million in revenue each year. The biopharmaceutical company earns $-36,200,000.00 in net income (profit) each year or ($3.95) on an earnings per share basis. How can I contact Palatin Technologies? Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The official website for the company is www.palatin.com. The biopharmaceutical company can be reached via phone at (609) 495-2200, via email at investors@palatin.com, or via fax at 609-495-2202. This page (NYSEAMERICAN:PTN) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.